Current management of the Zollinger-Ellison syndrome (Q38168242)

30 August 2017

Current management of the Zollinger-Ellison syndrome (English)

1 reference

30 August 2017

Geoffrey W Krampitz

1

1 reference

PubMed ID

24298844

30 August 2017

Jeffrey A Norton

series ordinal

2

1 reference

30 August 2017

1 January 2013

1 reference

30 August 2017

1 reference

30 August 2017

47

1 reference

30 August 2017

59-79

1 reference

Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas

30 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Reoperative surgery for the Zollinger-Ellison syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Neuroendocrine pancreatic tumors. Clinical findings in a prospective study of 84 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Zollinger-Ellison syndrome revisited: diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

The gastrinoma triangle: operative implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

7 January 2021

Surgery for gastrinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Imaging of gastrinomas by nuclear medicine methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Extrapancreatic, extraintestinal gastrinoma: effective treatment by surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

An immunohistochemical survey for neuroendocrine cells in regional pancreatic lymph nodes: a plausible explanation for primary nodal gastrinomas? Mayo Clinic Pancreatic Surgery Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Endocrine tumours of the gastrointestinal tract. Surgical treatment of neuroendocrine metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Survival impact of malignant pancreatic neuroendocrine and islet cell neoplasm phenotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Benign and malignant gastrinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Improved contemporary surgical management of insulinomas: a 25-year experience at the Massachusetts General Hospital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Resection of pancreatic neuroendocrine tumors: results of 70 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

50-year appraisal of gastrinoma: recommendations for staging and treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

One hundred thirty resections for pancreatic neuroendocrine tumor: evaluating the impact of minimally invasive and parenchyma-sparing techniques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Gastrinoma (duodenal and pancreatic).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Endocrine pancreatic tumors: factors correlated with survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Lymph nodes and survival in pancreatic neuroendocrine tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Pancreatic endocrine tumors: radiologic-clinicopathologic correlation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Pancreatic neuroendocrine tumors: radiographic calcifications correlate with grade and metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Prospective study of the ability of computed axial tomography to localize gastrinomas in patients with Zollinger-Ellison syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Multi-detector row CT of pancreatic islet cell tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Preoperative detection of pancreatic insulinomas on multiphasic helical CT.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Approaches to the diagnosis of gut neuroendocrine tumors: the last word (today).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

SPECT/CT hybrid imaging with 111In‐pentetreotide in assessment of neuroendocrine tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Changing treatment strategy for gastrinoma in patients with Zollinger-Ellison syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Evaluation of somatostatin-receptor scintigraphy for detecting neuroendocrine tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Imaging of neuroendocrine tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Endoscopic ultrasound in the detection of pancreatic islet cell tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Localization of Pancreatic Endocrine Tumors by Endoscopic Ultrasonography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Rare pancreatic neoplasms: the utility of endoscopic ultrasound-guided fine-needle aspiration-a large single center study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Intraoperative ultrasonographic localization of islet cell tumors. A prospective comparison to palpation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Metabolic remission with octreotide in patients with insulinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Value of surgery in patients with negative imaging and sporadic Zollinger-Ellison syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Microgastrinomas of the duodenum. A cause of failed operations for the Zollinger-Ellison syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Surgery to cure the Zollinger-Ellison syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Gastrinoma excision for cure. A prospective analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Acid suppression: Optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Gastrinoma: advances in localization and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Medical management of patients with Zollinger-Ellison syndrome who have had previous gastric surgery: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

The influence of total gastrectomy on survival in malignant Zollinger-Ellison tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Thirty years' experience with gastrinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Surgery for gastrinoma and insulinoma in multiple endocrine neoplasia type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Management of patients with Zollinger-Ellison syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Detection of duodenal gastrinomas by operative endoscopic transillumination. A prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Guidelines for diagnosis and therapy of MEN type 1 and type 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Neuroendocrine tumors of the pancreas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Advances in the systemic treatment of pancreatic neuroendocrine tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Promising advances in the treatment of malignant pancreatic endocrine tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Everolimus for advanced pancreatic neuroendocrine tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Activity of sunitinib in patients with advanced neuroendocrine tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2013.02.004

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YASU.2013.02.004

1 reference

30 August 2017

1 reference

PubMed ID

24298844